Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628832 · ClinicalTrials.gov registry record · NA
Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 12,000
- Enrollment target
NCT04628832: Completed NA study, sponsored by Columbia University.
NCT04628832 is a NA study that has completed, run by Columbia University. The registered enrollment target is 12,000 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (755% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04628832, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12,000 participants
- Enrollment target
Study Summary
Despite an enormous policy response, opioid prescribing remains well above historical levels and harms from opioids continue to mount. Nearly all states have Prescription Monitoring Programs (PMPs) to facilitate safer prescribing of opioids and other drugs, but research suggests these systems only deliver benefits when health care professionals are required to use them. Even with PMP mandates in place, providers may be unaware of the dangers of co-prescribing opioids with benzodiazepines or gabapentinoids, which include increased risk of overdose and death. Working with the Minnesota state government, the investigators will mail letters to guideline-discordant opioid prescribers that either highlight an upcoming legally mandated requirement to check the PMP before prescribing an opioid, inform and educate providers about patients filling concurrent prescriptions and the dangers of such co-prescribing, or both. Study participants will be randomized to receive no intervention or one of the three treatment letters. Using administrative data, the investigators will track effects of the letters on not only prescribing but also PMP usage and queries. Findings form the multiplicity of treatment messages and outcomes will shed light on the mechanisms driving overprescribing. Results will inform future work by state and local policymakers to make opioid prescribing safer.
Primary Outcome
The number of patients with co-prescriptions from the prescriber in the 60 days after the letters are sent.
Interventions
- BEHAVIORAL PMP Use Mandate Letter
- BEHAVIORAL Prescribing Information Letter
- BEHAVIORAL Prescribing Information + PMP Use Mandate Letter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,000 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2021-07-12 |
| Phase | NA |
What the finished NCT04628832 record still lists
NCT04628832 is an interventional study that assigns participants to a tested intervention. Its 12,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (755% higher).
The record links to 0 conditions, and to 3 interventions - of which PMP Use Mandate Letter is the first listed.
NCT04628832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04628832 about?
NCT04628832 is a clinical study titled "Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms". Despite an enormous policy response, opioid prescribing remains well above historical levels and harms from opioids continue to mount. Nearly all states have Prescription Monitoring Programs (PMPs) to facilitate safer prescribing of opioids and other drugs, but research suggests these systems only d...
What is the current status of trial NCT04628832?
This trial is currently completed. It is a NA study. The enrollment target is 12,000 participants. The study started on 2021-04-15. Estimated completion is 2021-07-12.
What interventions are being tested in trial NCT04628832?
The interventions under investigation include: PMP Use Mandate Letter (BEHAVIORAL), Prescribing Information Letter (BEHAVIORAL), Prescribing Information + PMP Use Mandate Letter (BEHAVIORAL).
Who is sponsoring clinical trial NCT04628832?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04628832's enrollment target sits among peer trials
12,000 14th of 2000 higher than 1,987 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06059963 · 12,000 participants
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
- NCT06273618 · 12,000 participants · NA
iLookOut Micro-learning to Improve Knowledge Retention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI